MedTrace Logo

Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States

NCT01031277 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2011-05-25

No results posted yet for this study

Summary

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations:

* Primary/secondary prevention patients.
* Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

* Primary/secondary prevention patients.
* Patients with metabolic syndrome.

Conditions

Sponsors & Collaborators

  • AstraZeneca

    lead INDUSTRY

  • Clinart International

    collaborator INDUSTRY

Principal Investigators

  • Prof. Wael Al Mahmeed · Shaikh Khalifa Medical City

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01031277 on ClinicalTrials.gov